Approval · Notice of Compliance 11374 · 2010
ALIMTA: Notice of Compliance 11374
Issued May 11, 2010
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 11374
- Date
- May 11, 2010
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: Maintenance treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer, in a good performance status patients without disease progression immediately following four cycles of first-line platinum doublet chemotherapy, excluding pemetrexed
- Therapeutic class
- Antineoplastic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ALIMTA | Not yet assigned | — |
Medicinal ingredients
- PEMETREXED DISODIUM 500 MG per VIAL
- PEMETREXED DISODIUM 100 MG per VIAL